Contact Us

• webcasts

TEXT SIZE

print share |

12.17.06   A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
	Stefan Knop, MD Universitätsklinikums Würzburg (University Clinic of Wuerzburg) Würzburg, Germany

---

12.17.06   A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma
	Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, NY

---

12.17.06   A Subset Study of Lenalidomide/Dexamethasone vd Dexamethasone Alone After Thalidomide Therapy in Relapsed/Refractory Myeloma
	Michael Wang, MD MD Anderson Cancer Center Houston, Texas USA

---

12.17.06   Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma
	Heinz Ludwig, MD Wilhelminenspital der Stadt Wein Vienna, Austria

---

12.17.06   Combination of Revlimid and Velcade in the Treatment of Relapsed/Refractory Myeloma
	Paul G. Richardson, MD Dana Farber Cancer Institute Boston, Massachusetts USA

---

12.17.06   Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed/Refractory CD56-Positive Myeloma
	Asher A. Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, NY

---

12.17.06   Phase I/II Study of a Combination of Velcade, Melphalan, Prednisone, and Thalidomide (VMPT) for Relapsed Myeloma
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy

---

12.17.06   Phase I/II Study of Oral Cyclophosphamide, Prednisone, and Velcade in Patients with Relapsed/Refractory Myeloma
	Donna E. Reece, MD Princess Margaret Hospital Toronto, Canada

---

12.17.06   Phase III International Randomized Study of Velcade vs Velcade/Doxil in Relapsed/Refractory Myeloma
	Robert Z. Orlowski, MD Lineberger Cancer Center University of North Carolina Chapel Hill, NC

---

12.17.06   Revlimid in Combination with Dex is More Effective than Dexamethasone Alone at First Relapse
	Edward A. Stadtmauer, MD Hospital of the University of Pennsylvania Philadelphia, PA

---